Similarly, IFN-α2b treatment of COVID-19 patients as a single agent or in combination with arbidol significantly reduced the duration of SARS-CoV-2 in the upper respiratory tract and reduced the duration of IL-6 and C-Reactive Protein (CRP) inflammatory markers in the blood [45]. This evidence concerns the gene CRP and COVID-19.